Less than one in 10 patients who could benefit from obesity jabs including Wegovy have access to them, states the WHO as it issues its first advice on the therapies.
With over a billion people worldwide currently obese, it is urging increased and just availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"The new guidance acknowledges that obesity is a lifelong illness that can be managed with thorough and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are key obstacles to widespread availability to the injections that can help people shift significant weight, says the organization.
Weight-Loss Drug Scarcity
Even in the present most favorable case, the production of these medications would only suffice for about 100 million people – less than 10% of the global need, per the WHO.
The recommendation encourages governments and firms to expand availability, by strategies including licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.
The Way Obesity Jabs Operate
These medications replicate a natural hormone to slow digestion, suppress the appetite and enhance the sense of being full so individuals eat less.
Patients commonly begin shedding pounds after several weeks of commencing the once-weekly jabs.
Studies points to people may see weight return within a year of stopping the medication, because their usual appetite return.
To be above a healthy weight elevates your chance for developing diseases, including diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight impacts individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, as per the health agency.
